Albinterferon Alfa 2b Single Dose in Japanese Chronic Hepatitis C Patients
NCT00724776 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30
Last updated 2020-12-08
Summary
This study will evaluate safety, tolerability, pharmacokinetics and pharmacodynamics of albinterferon alfa 2b (alb-IFN) single dose in Japanese chronic hepatitis C patients
Conditions
- Chronic Hepatitis C
Interventions
- BIOLOGICAL
-
Albinterferon alfa 2b
recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
Sponsors & Collaborators
- lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Max Age
- 69 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-07-31
- Primary Completion
- 2009-07-31
Countries
- Japan
Study Locations
More Related Trials
-
A Study of Albuferon With Ribavirin in Interferon Treatment Experienced Subjects With Chronic Hepatitis C
NCT00097435 ·Status: COMPLETED ·Phase: PHASE2
-
Pegylated Alfa-2b Interferon Therapy of Patients With Hepatitis C-related Cirrhosis and High Liver Cell Proliferation (P02733/MK-4031-085)
NCT00759109 ·Status: COMPLETED ·Phase: PHASE3
-
Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial
NCT01579474 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of MP-424, Peginterferon Alfa-2a (PEG-IFN Alfa-2a), and Ribavirin(RBV) in Treatment-Naïve or Relapsed Hepatitis C
NCT01753557 ·Status: COMPLETED ·Phase: PHASE3
-
Comparison in Efficacy and Safety Between Interferon Alfacon-1 Alone and Concomitant Dosing With Ribavirin for the Treatment of Hepatitis C
NCT00239252 ·Status: COMPLETED ·Phase: PHASE3
-
Phase III Randomized Study of High Vs Standard Dose of Interferon Alfa for Chronic Hepatitis C
NCT00004804 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy Study of New Therapeutic Schedules in Naive Hepatitis C Virus (HCV) Patients Infected With Genotype 3 (HCV-3)
NCT01121705 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of PegIntron Plus Rebetol in Patients With Chronic Hepatitis C in Japan, Excluding (1) Subjects With HCV Genotype 1 and High Viral Load, and (2) Interferon-naïve Subjects With Low Viral Load (Study P04841)(COMPLETED)
NCT00724230 ·Status: COMPLETED
-
Efficacy of Pegylated Interferon Alone in Egyptian Patients With Acute Hepatitis C (ANRS 1213)
NCT00158522 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of MP-424/Peginterferon Alfa-2b/Ribavirin Combination in Treatment-Naïve Patients With Chronic Hepatitis C
NCT00780416 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Peginterferon Alfa-2a in Combination With Ribavirin in Chronic Hepatitis C (CHC) Patients With Compensated Liver Cirrhosis (LC)
NCT00304551 ·Status: COMPLETED ·Phase: PHASE3
-
Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)
NCT01405560 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3
NCT00656006 ·Status: COMPLETED ·Phase: PHASE2
-
A Multicenter Phase 3 Study of Interferon-beta-1a for the Treatment of Chronic Hepatitis C in Asian Subjects
NCT00249860 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients
NCT00996476 ·Status: COMPLETED ·Phase: PHASE2
-
Low-dose Peg-interferon Plus Ribavirin (IFN/RBV) for Prevention of Hepatocellular Carcinoma (HCC) Recurrence in Patients Who Had Surgery to Remove Primary HCC
NCT00375661 ·Status: COMPLETED ·Phase: PHASE4
-
Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients
NCT00495131 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of Single Doses of ABT-072 in Japanese Healthy Male Adults
NCT01081483 ·Status: COMPLETED ·Phase: PHASE1
-
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha-2b and Ribavirin) in Japanese Patients
NCT01016912 ·Status: COMPLETED ·Phase: PHASE2
-
Chronic Hepatitis C Treatment by Pegylated Interferon and Ribavirin in Naive Egyptian Patients (ANRS 1211)
NCT00158496 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Relapsed After Treatment (MK-7009-044)
NCT01405937 ·Status: COMPLETED ·Phase: PHASE3
-
Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C
NCT00491244 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of MP-424, Peginterferon Alfa-2b, and Ribavirin in Patients With Chronic Hepatitis C Who Relapsed After Previous Interferon Based Therapy
NCT00780910 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care in Japanese Patients (Pegylated-interferon Alpha-2a and Ribavirin)
NCT01017575 ·Status: COMPLETED ·Phase: PHASE2
-
PEG-IFN Plus Ribavirin Combination Therapy for Older Patients
NCT00956982 ·Status: UNKNOWN ·Phase: NA